Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $10.00

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of analysts have recently issued reports on the stock. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, November 21st. Stephens initiated coverage on Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target on the stock. Finally, Royal Bank of Canada raised their price objective on Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st.

Pyxis Oncology Trading Down 3.0 %

Pyxis Oncology stock opened at $1.63 on Friday. The company has a 50-day moving average price of $3.03 and a 200 day moving average price of $3.34. Pyxis Oncology has a 12-month low of $1.51 and a 12-month high of $6.85. The stock has a market cap of $96.94 million, a P/E ratio of -1.58 and a beta of 1.00.

Insider Activity at Pyxis Oncology

In other Pyxis Oncology news, CFO Pamela Ann Connealy purchased 88,850 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was bought at an average price of $1.96 per share, with a total value of $174,146.00. Following the transaction, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.80% of the stock is currently owned by company insiders.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently modified their holdings of PYXS. Fullcircle Wealth LLC purchased a new position in Pyxis Oncology in the second quarter worth approximately $40,000. Intech Investment Management LLC purchased a new stake in shares of Pyxis Oncology during the 3rd quarter worth $55,000. SG Americas Securities LLC acquired a new position in shares of Pyxis Oncology during the third quarter worth $58,000. MetLife Investment Management LLC increased its holdings in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after buying an additional 5,484 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Pyxis Oncology in the second quarter valued at $65,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.